CD19 and acute myeloid leukemia: Remarkable results were achieved with CAR-modified T-cells targeting CD19 in relapsed/refractory patients with diffuse large B-cell lymphoma (DLBCL) [100] and pediatric B-cell acute lymphoblastic leukemia (ALL) [101] (50–90% CR), which inspired development of CAR-T cellular therapy for other indications, such as AML.